South Korea-based biopharmaceutical company GC Biopharma has announced that the Egyptian Drug Authority (EDA) has approved its quadrivalent flu vaccine called GC FLU Quadrivalent Pre-filled syringe injective.
The approval of the quadrivalent flu vaccine is GC Biopharma’s first in Africa.
Every year, GC FLU has increased the volume of its exports and the number of its markets, said GC Biopharma. The product is based on the company’s seasonal flu vaccine production technology.
The biopharmaceutical company said that the expansion shows the safety and effectiveness of the Korean-made vaccine to the world.
GC Biopharma stated that the trend of shifting towards quadrivalent flu vaccines is evident not only in the procurement market led by international organisations but also in the individual private markets.
The company said that its intention is to target both international organisations’ procurement markets and the private markets to leverage synergies and enhance their sales and profitability.
GC Biopharma intends to further extend its global reach, which has been focused on Southeast Asia and Latin America, to the Middle East and Africa by utilising the EDA approval.
Simultaneously, the South Korean company will aim to enter the private markets of individual countries based on its strong presence in the procurement markets of international organisations.
GC Biopharma president EC Huh said: “We will continue to expand our global market share based on our half-century vaccine technology and manufacturing capabilities.”
The company is engaged in the production of plasma protein and vaccines globally and provides healthcare solutions, life-saving and life-sustaining protein therapeutics, and vaccines.
